JP2015521593A5 - - Google Patents

Download PDF

Info

Publication number
JP2015521593A5
JP2015521593A5 JP2015516723A JP2015516723A JP2015521593A5 JP 2015521593 A5 JP2015521593 A5 JP 2015521593A5 JP 2015516723 A JP2015516723 A JP 2015516723A JP 2015516723 A JP2015516723 A JP 2015516723A JP 2015521593 A5 JP2015521593 A5 JP 2015521593A5
Authority
JP
Japan
Prior art keywords
seq
aqueous composition
cdr2
cdr3
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015516723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015521593A (ja
JP6265978B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/054777 external-priority patent/WO2013186700A1/en
Publication of JP2015521593A publication Critical patent/JP2015521593A/ja
Publication of JP2015521593A5 publication Critical patent/JP2015521593A5/ja
Application granted granted Critical
Publication of JP6265978B2 publication Critical patent/JP6265978B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015516723A 2012-06-12 2013-06-11 抗体製剤 Active JP6265978B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261658472P 2012-06-12 2012-06-12
US61/658,472 2012-06-12
PCT/IB2013/054777 WO2013186700A1 (en) 2012-06-12 2013-06-11 Antibody formulation

Publications (3)

Publication Number Publication Date
JP2015521593A JP2015521593A (ja) 2015-07-30
JP2015521593A5 true JP2015521593A5 (enExample) 2016-06-16
JP6265978B2 JP6265978B2 (ja) 2018-01-24

Family

ID=48914378

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015516723A Active JP6265978B2 (ja) 2012-06-12 2013-06-11 抗体製剤

Country Status (37)

Country Link
US (4) US9216219B2 (enExample)
EP (3) EP2858671B1 (enExample)
JP (1) JP6265978B2 (enExample)
KR (1) KR102124820B1 (enExample)
CN (1) CN104363920B (enExample)
AR (1) AR091413A1 (enExample)
AU (1) AU2013276112B2 (enExample)
BR (1) BR112014030820B1 (enExample)
CA (1) CA2875386C (enExample)
CL (1) CL2014003370A1 (enExample)
CO (1) CO7151487A2 (enExample)
CY (1) CY1122181T1 (enExample)
DK (2) DK3593814T3 (enExample)
EA (1) EA033373B1 (enExample)
EC (1) ECSP15017314A (enExample)
ES (1) ES2751659T3 (enExample)
FI (1) FI3593814T3 (enExample)
GT (1) GT201400285A (enExample)
HR (1) HRP20191827T1 (enExample)
HU (1) HUE045523T2 (enExample)
IL (1) IL235966B (enExample)
LT (2) LT2858671T (enExample)
MA (1) MA37616A1 (enExample)
MX (1) MX363380B (enExample)
MY (1) MY179818A (enExample)
NZ (1) NZ630885A (enExample)
PE (1) PE20150200A1 (enExample)
PH (1) PH12014502778B1 (enExample)
PL (1) PL2858671T3 (enExample)
PT (2) PT3593814T (enExample)
RS (1) RS67957B1 (enExample)
SG (1) SG11201408174UA (enExample)
SI (1) SI2858671T1 (enExample)
TN (1) TN2014000488A1 (enExample)
TW (1) TWI653983B (enExample)
WO (1) WO2013186700A1 (enExample)
ZA (1) ZA201408547B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2688093T3 (es) 2010-01-06 2018-10-30 Dyax Corp. Proteínas de unión a calicreína plasmática
US9458240B2 (en) * 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
JP2016513682A (ja) 2013-03-15 2016-05-16 ダイアックス コーポレーション 抗血漿カリクレイン抗体
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CN113350278B (zh) 2013-10-24 2023-03-24 阿斯利康(瑞典)有限公司 稳定的水性抗体配制品
CN104730237A (zh) * 2013-12-23 2015-06-24 国家纳米科学中心 试纸及其应用以及检测甲胎蛋白抗原、乙肝表面抗原或HIV的gp41抗体的方法
KR20240049627A (ko) 2014-01-21 2024-04-16 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
JP2017514458A (ja) 2014-03-12 2017-06-08 プロセナ バイオサイエンシーズ リミテッド Ｌｇ４−５に対して特異的な抗−ラミニン４抗体
KR20160127825A (ko) 2014-03-12 2016-11-04 프로테나 바이오사이언시즈 리미티드 항-mcam 항체 및 관련된 사용 방법
EP3122782A4 (en) 2014-03-27 2017-09-13 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
KR101597037B1 (ko) 2014-06-26 2016-02-24 엘지디스플레이 주식회사 구동소자의 전기적 특성 편차를 보상할 수 있는 유기발광 표시장치
TWI738632B (zh) 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
IL254292B2 (en) * 2015-03-30 2026-01-01 Dyax Corp Plasma kallikrein inhibitors and their uses for preventing the onset of hereditary angioedema
EP3350226A2 (en) * 2015-09-16 2018-07-25 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
CN108367072B (zh) * 2015-12-07 2022-12-27 默克专利股份有限公司 含抗-pd-l1抗体avelumab的水性药物制剂
BR112018011622A2 (pt) 2015-12-11 2018-11-27 Dyax Corp método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
WO2017104778A1 (ja) * 2015-12-18 2017-06-22 アステラス製薬株式会社 抗ヒトｔｓｌｐ受容体抗体含有医薬組成物
KR102389489B1 (ko) * 2016-06-16 2022-04-22 얀센 백신스 앤드 프리벤션 비.브이. Hiv 백신 제형
IL326918A (en) 2016-10-19 2026-05-01 Invenra Inc Antibody structures
JP7681879B2 (ja) 2016-12-22 2025-05-23 ウニヴェルシタ・デリ・ストゥディ・マニャ・グレチア・カタンツァーロ Ｃｄ４３の固有のシアログリコシル化がん関連エピトープを標的化するモノクローナル抗体
BR112019018022A2 (pt) * 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
UA129583C2 (uk) * 2017-03-06 2025-06-11 Мерк Патент Гмбх Водний фармацевтичний склад, який містить антитіло проти pd-l1 авелумаб
US11639391B2 (en) * 2017-04-18 2023-05-02 Dr. Reddy's Laboratories Limited Stable liquid pharmaceutical composition
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
BR112020001703B1 (pt) * 2017-07-27 2024-01-02 Alexion Pharmaceuticals, Inc Solução aquosa estável compreendendo um anticorpo anti-c5, método para produção desta solução, uso da mesma para tratar uma condição associada ao complemento e kit terapêutico compreendendo a mesma
AU2018321335B2 (en) * 2017-08-22 2025-08-14 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
PE20210042A1 (es) 2017-10-06 2021-01-08 Prothena Biosciences Ltd Metodos para detectar transtiretina
AU2018375356A1 (en) * 2017-11-29 2020-05-14 Neotope Neuroscience Limited Lyophilized formulation of a monoclonal antibody against transthyretin
CA3102349A1 (en) 2018-06-05 2019-12-12 King's College London Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
EP3814373A1 (en) 2018-06-28 2021-05-05 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
AU2019407063B2 (en) * 2018-12-18 2024-07-04 Novartis Ag Protein solution formulation containing high concentration of an anti-VEGF antibody
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
JP2022521624A (ja) * 2019-02-26 2022-04-11 イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド 抗ｃｄ４７抗体を含む製剤、その調製方法および使用
WO2021091706A1 (en) 2019-11-06 2021-05-14 Novartis Ag Treatment for sjögren's syndrome
CN113116812A (zh) * 2019-12-30 2021-07-16 百奥泰生物制药股份有限公司 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用
CA3167336A1 (en) 2020-01-13 2021-07-22 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
EP4094777A4 (en) * 2020-01-21 2024-01-24 Innovent Biologics (Suzhou) Co., Ltd. RECOMBINANT FULLY HUMAN MONOCLONAL ANTI-TIGITE ANTIBODIES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF
CN116194478A (zh) 2020-06-24 2023-05-30 阿雷克森制药公司 皮下（sc）施用抗c5抗体治疗补体相关病症
EP4192870A1 (en) * 2020-08-04 2023-06-14 Novartis AG Treatment of cll
EP4192869A1 (en) 2020-08-04 2023-06-14 Novartis AG Treatment of b cell malignancies
US20220193238A1 (en) * 2020-12-17 2022-06-23 Astrazeneca Ab Anti-il5r antibody formulations
CN115073598B (zh) * 2021-03-15 2024-02-20 盛禾(中国)生物制药有限公司 一种抗baffr抗体及其应用
WO2022234439A1 (en) 2021-05-04 2022-11-10 Novartis Ag Treatment for systemic lupus erythematosus using anti-baffr antibodies
KR20240004760A (ko) 2021-05-04 2024-01-11 노파르티스 아게 항-baffr 항체를 사용한 루푸스 신염의 치료
CN118317975A (zh) * 2021-09-29 2024-07-09 蜻蜓治疗公司 靶向baff-r的抗体及其用途
KR20250120995A (ko) 2022-11-07 2025-08-11 업스트림 바이오, 인크. 항-인간 tslp 수용체 항체를 포함하는 약제학적 조성물 및 이를 사용하는 방법
CN118681009A (zh) * 2023-03-21 2024-09-24 百奥泰生物制药股份有限公司 一种复方制剂及其应用
CN116712390B (zh) * 2023-08-04 2023-11-14 上海览屹医药科技有限公司 一种高浓度高稳定性的抗体制剂及其制备方法
WO2025257781A1 (en) * 2024-06-14 2025-12-18 Novartis Ag Treatment of systemic sclerosis using anti-baff-r antibodies
WO2025263459A1 (ja) * 2024-06-17 2025-12-26 学校法人神戸薬科大学 バイオ医薬品組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
CA2375527A1 (en) 1999-06-23 2000-12-28 Oregon Health And Science University Method for enhancing hematopoiesis
ATE440959T1 (de) 2000-06-28 2009-09-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
ES2392073T3 (es) 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
EP1946776B1 (en) 2002-02-27 2017-01-18 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EA200701211A1 (ru) * 2004-12-31 2007-12-28 Дженентек, Инк. Полипептиды, которые связываются с br3, и их применение
EA024492B1 (ru) * 2008-07-17 2016-09-30 Новартис Аг Антитела, специфически связывающиеся с baffr, и их применение
EP2501367B1 (en) * 2009-11-17 2015-01-21 Ipsen Pharma S.A.S. Formulation for HGH and RHIGF-1 combination
US9458240B2 (en) * 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
WO2013083497A1 (en) 2011-12-06 2013-06-13 F. Hoffmann-La Roche Ag Antibody formulation
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation

Similar Documents

Publication Publication Date Title
AR091413A1 (es) Formulacion de anticuerpos
JP2013543505A5 (enExample)
FI3506886T3 (fi) Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä
AR124140A2 (es) Formulaciones de anticuerpos
HRP20191199T1 (hr) Formulacije protutijela anti-prolaktinskog receptora
JP2017031213A5 (enExample)
JP2015519382A5 (enExample)
NZ730821A (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
AR095451A1 (es) Formulación de anticuerpos
JP2013517277A5 (enExample)
RU2015119547A (ru) Стабильный низковязкий состав с антителом
JP2012136541A5 (enExample)
JP2015007098A5 (enExample)
RU2021137159A (ru) Стабильные водные составы на основе антител
JP2016539921A5 (enExample)
HRP20191137T1 (hr) Formulacije otopina konstruiranih anti-il-23p19 antitijela
AU2016204185A1 (en) Methods of administering beta7 integrin antagonists
AR077225A1 (es) Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza
RU2015134422A (ru) Применение левоцитиризина и монтелукаста при лечении васкулита
JP2016505572A5 (enExample)
JP2019501920A5 (enExample)
EP4506016A3 (en) Pharmaceutical composition containing anti-human tslp receptor antibody
JP2015513535A5 (enExample)
JP2016512247A5 (enExample)
AR130115A2 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf